Literature DB >> 24455448

Risk of Death among HIV Co-Infected Multidrug Resistant Tuberculosis Patients, Compared To Mortality in the General Population of South Africa.

Samuel Om Manda1, Lieketseng J Masenyetse2, Joey L Lancaster3, Martie L van der Walt3.   

Abstract

BACKGROUND: Even though highly effective drugs are available in South Africa, multidrug resistant tuberculosis (MDR-TB) patients with HIV infection have higher mortality compared to HIV-uninfected MDR-TB patients. This trend has been observed in similar countries with high HIV prevalence. This study sought to determine excess mortality attributable to HIV among MDR-TB patients in South Africa using relative survival methods.
METHODS: Data available were from a cohort of 2079 MDR-TB patients enrolled in a Standardized Programmatic Management of MDR-TB from 2000 to 2004 in South Africa. A Poisson-based model adjusted for age, gender, year of diagnosis, TB history, and resistance to ethambutol, anti-TB injectable drugs and fluoroquinolones antibiotics was constructed to assess the excess mortality among HIV co-infected MDR-TB patients. Excess hazard ratios (EHRs) were used to describe the effect of the predictors on net mortality, controlling for the general mortality in the South African population.
RESULTS: Death was recorded on 1619 patients, of whom 367 (22.7%) had died within 2 years. Out of the 1413 patients that tested for HIV infection, 554 (39.2%) tested positive. Excess mortality was higher in HIV infected, compared to HIV uninfected, MDR-TB patients (adjusted excess hazard ratio, 5.6 [95% CI, 3.2-9.7]); in patients whose TB isolates' resistance to ethambutol and kanamycin was unknown (3.7 [2.1-6.2] and 4.87 [1.9-13.3], respectively) vs. known. There were no differences in excess mortality between age and gender of the patient, year of diagnosis and TB history.
CONCLUSION: Adjusting for some important predictors, MDR-TB patients with HIV infection experienced higher excess mortality compared to HIV-uninfected MDR-TB patients, after accounting for the general mortality in South Africa. An appropriate, though complex method has produced predictor effect estimates similar to those obtained from classical methods. Thus, the use of relative survival methods should be encouraged in the analysis of causespecific mortality, when ascertainment of cause of death is inaccurate or unknown.

Entities:  

Keywords:  HIV; Relative mortality; South Africa; Tuberculosis

Year:  2013        PMID: 24455448      PMCID: PMC3894364          DOI: 10.4172/2155-6113.S3-007

Source DB:  PubMed          Journal:  J AIDS Clin Res


  26 in total

1.  Counting the dead and what they died from: an assessment of the global status of cause of death data.

Authors:  Colin D Mathers; Doris Ma Fat; Mie Inoue; Chalapati Rao; Alan D Lopez
Journal:  Bull World Health Organ       Date:  2005-03-16       Impact factor: 9.408

2.  Determinants of multidrug-resistant tuberculosis in South Africa: results from a national survey.

Authors:  K Weyer; J Brand; J Lancaster; J Levin; M van der Walt
Journal:  S Afr Med J       Date:  2007-11

Review 3.  HIV-TB co-infection: epidemiology, diagnosis & management.

Authors:  S K Sharma; Alladi Mohan; Tamilarasu Kadhiravan
Journal:  Indian J Med Res       Date:  2005-04       Impact factor: 2.375

4.  HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up.

Authors:  P M Kelly; R G Cumming; J M Kaldor
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 May-Jun       Impact factor: 2.184

Review 5.  Multidrug and extensively drug-resistant TB (M/XDR-TB): problems and solutions.

Authors:  Rajendra Prasad
Journal:  Indian J Tuberc       Date:  2010-10

6.  Making relative survival analysis relatively easy.

Authors:  Maja Pohar; Janez Stare
Journal:  Comput Biol Med       Date:  2007-06-19       Impact factor: 4.589

Review 7.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

8.  Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.

Authors:  Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

9.  Predicted trends in long-term breast cancer survival in England and Wales.

Authors:  L M Woods; B Rachet; N Cooper; M P Coleman
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

Review 10.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more
  11 in total

1.  A Novel Reporter Phage To Detect Tuberculosis and Rifampin Resistance in a High-HIV-Burden Population.

Authors:  Max R O'Donnell; Alexander Pym; Paras Jain; Vanisha Munsamy; Allison Wolf; Farina Karim; William R Jacobs; Michelle H Larsen
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

2.  Treatment Adherence Among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa.

Authors:  Fay Stephens; Neel R Gandhi; James C M Brust; Koleka Mlisana; Pravi Moodley; Salim Allana; Angie Campbell; Sarita Shah
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

3.  The complex relationship between human immunodeficiency virus infection and death in adults being treated for tuberculosis in Cape Town, South Africa.

Authors:  Muhammad Osman; James A Seddon; Rory Dunbar; Heather R Draper; Carl Lombard; Nulda Beyers
Journal:  BMC Public Health       Date:  2015-06-18       Impact factor: 3.295

4.  Predictors of mortality in a cohort of tuberculosis/HIV co-infected patients in Southwest Ethiopia.

Authors:  Hailay Gesesew; Birtukan Tsehayneh; Desalegn Massa; Amanuel Gebremedhin; Hafte Kahsay; Lillian Mwanri
Journal:  Infect Dis Poverty       Date:  2016-12-05       Impact factor: 4.520

5.  Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania.

Authors:  Edson W Mollel; Jaffu O Chilongola
Journal:  J Trop Med       Date:  2017-07-20

6.  Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.

Authors:  Mathieu Bastard; Elisabeth Sanchez-Padilla; Philipp du Cros; Atadjan Karimovich Khamraev; Nargiza Parpieva; Mirzagaleg Tillyashaykov; Armen Hayrapetyan; Kamene Kimenye; Shazina Khurkhumal; Themba Dlamini; Santiago Fadul Perez; Alex Telnov; Cathy Hewison; Francis Varaine; Maryline Bonnet
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

7.  Risk factors for mortality in TB patients: a 10-year electronic record review in a South African province.

Authors:  J Christo Heunis; N Gladys Kigozi; Perpetual Chikobvu; Sonja Botha; Hcj Dingie van Rensburg
Journal:  BMC Public Health       Date:  2017-01-06       Impact factor: 3.295

8.  Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies.

Authors:  Dumessa Edessa; Fuad Adem; Bisrat Hagos; Mekonnen Sisay
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

9.  Effectiveness and safety of concurrent use of first-line antiretroviral and antituberculous drugs in rwanda.

Authors:  Justin Ntokamunda Kadima; Marie Françoise Mukanyangezi; Claude Bernard Uwizeye
Journal:  J Trop Med       Date:  2014-01-30

10.  Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.

Authors:  Jennifer Furin; Grania Brigden; Erica Lessem; Michael Rich; Laura Vaughan; Sharonann Lynch
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.